AI assistant
BeOne Medicines Ltd. — Director's Dealing 2024
Mar 4, 2024
30073_dirs_2024-03-04_27cf1e05-f803-4b22-8b01-d9a8c1c3d143.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BeiGene, Ltd. (BGNE)
CIK: 0001651308
Period of Report: 2024-02-29
Reporting Person: Wang Julia Aijun (Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-02-29 | American Depositary Shares | S | 397 | $167.08 | Disposed | 0 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Ordinary Shares | 320086 | Direct |
Footnotes
F1: Each American Depositary Share represents 13 Ordinary Shares.
F2: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of February 28, 2022, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control.